GlassScriptPhysician profile
Erik John Richardson
NPI 1942307640
$2,470.62
in general payments reported to CMS, 2019-2025
35 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $154 · 2024: $545 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $410.22 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $255.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $223.46 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $212.49 | 2019-2025 | |
| Lilly USA, LLC | $174.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.25 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $91.14 | 2019-2025 | Spravato |
| Phathom Pharmaceuticals, INC. | $76.79 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $70.26 | 2024-2025 | |
| Exact Sciences Corporation | $69.44 | 2024-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $67.05 | 2024 | Yupelri |
| Corcept Therapeutics | $61.15 | 2025 | Korlym |
| Abbott Laboratories | $59.51 | 2024-2025 | Freestyle Libre 3, Eterna, Proclaim |
| Dexcom, INC. | $43.16 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $39.08 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $38.80 | 2025 | Eliquis |
| Merck Sharp & Dohme LLC | $38.35 | 2019-2020 | |
| Axsome Therapeutics, INC. | $38.09 | 2025 | Symbravo, Auvelity |
| Glaxosmithkline, LLC. | $36.78 | 2025 | Trelegy Ellipta |
| Insulet Corporation | $27.98 | 2025 | Omnipod |
| Vertex Pharmaceuticals Incorporated | $24.78 | 2025 | |
| Astellas Pharma US INC | $23.38 | 2024 | Veozah |
| Boston Scientific Corporation | $22.84 | 2025 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $21.74 | 2024 | Amvuttra |
| Philips North America LLC | $21.13 | 2019 | |
| Stryker Corporation | $20.85 | 2024 | Mako, Triathlon |
| Ethicon US, LLC | $20.21 | 2019 | |
| Viatris Specialty LLC | $20.08 | 2025 | Yupelri |
| Recor Medical INC | $19.48 | 2025 | Paradise Ultrasound Renal Denervation System |
| Grifols USA, LLC | $18.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.70 | 2024 | Trintellix |
| Organon LLC | $16.75 | 2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $13.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.37 | 2019 | |
| Corium, LLC | $8.80 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.